Hamaluba Mainga, Kandasamy Rama, Ndimah Susan, Morton Richard, Caccamo Marisa, Robinson Hannah, Kelly Sarah, Field Aimee, Norman Lily, Plested Emma, Thompson Ben A V, Zafar Azhar, Kerridge Simon A, Lazarus Rajeka, John Tessa, Holmes Jane, Fenlon Shannon N, Gould Katherine A, Waight Pauline, Hinds Jason, Crook Derrick, Snape Matthew D, Pollard Andrew J
From the Oxford Vaccine Group (MH, RK, SN, MC, HR, SK, AF, LN, EP, SAK, RL, TJ, MDS, AJP), Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford; Guy's and St Thomas' National Health Service Foundation Trust (RM), London; Department of Primary Healthcare Sciences (BAVT), University of Oxford, Oxford; Northamptonshire Teaching Primary Care Trust (AZ), National Health Service, Northamptonshire; Centre for Statistics in Medicine (JH), University of Oxford, Oxford; Health Protection Services (PW), Public Health England; Division of Clinical Sciences (SNF, KAG, JH), St. George's University of London, London; and Nuffield Department of Clinical Medicine (DC), University of Oxford, Oxford, UK.
Medicine (Baltimore). 2015 Jan;94(1):e335. doi: 10.1097/MD.0000000000000335.
Using nasopharyngeal carriage as a marker of vaccine impact, pneumococcal colonization and its relation to invasive disease were examined in children, their parents, and older adults in the United Kingdom following introduction of 7-valent pneumococcal conjugate vaccine (PCV7) and prior to 13-valent pneumococcal conjugate vaccine (PCV13).A cross-sectional observational study was conducted, collecting nasopharyngeal swabs from children aged 25 to 55 months who had previously received 3 doses of PCV7, their parents, and adults aged ≥65 years. Pneumococcal serotyping was conducted according to World Health Organization guidelines with nontypeable isolates further analyzed by molecular serotyping. A national invasive disease surveillance program was conducted throughout the corresponding period.Pneumococcus was isolated from 47% of children, 9% of parents, and 2.2% of older adults. For these groups, the percentage of serotypes covered by PCV7 were 1.5%, 0.0%, and 15.4%, with a further 20.1%, 44.4%, and 7.7% coverage added by those in PCV13. In each group, the percentage of disease due to serotypes covered by PCV7 were 1.0%, 7.4% and 5.1% with a further 65.3%, 42.1%, and 61.4% attributed to those in PCV13.The prevalence of carriage is the highest in children, with direct vaccine impact exemplified by low carriage and disease prevalence of PCV7 serotypes in vaccinated children, whereas the indirect effects of herd protection are implied by similar observations in unvaccinated parents and older adults.
以鼻咽部携带作为疫苗影响的标志物,在英国引入7价肺炎球菌结合疫苗(PCV7)后且13价肺炎球菌结合疫苗(PCV13)引入之前,对儿童、其父母及老年人的肺炎球菌定植情况及其与侵袭性疾病的关系进行了研究。开展了一项横断面观察性研究,收集了25至55个月龄且此前已接种3剂PCV7的儿童、其父母以及65岁及以上成年人的鼻咽拭子。根据世界卫生组织指南进行肺炎球菌血清分型,对不可分型菌株进一步通过分子血清分型进行分析。在相应期间开展了一项全国侵袭性疾病监测项目。肺炎球菌在47%的儿童、9%的父母以及2.2%的老年人中被分离出。对于这些群体,PCV7覆盖的血清型百分比分别为1.5%、0.0%和15.4%,PCV13覆盖的血清型又分别增加了20.1%、44.4%和7.7%。在每个群体中,由PCV7覆盖的血清型导致的疾病百分比分别为1.0%、7.4%和5.1%,由PCV13覆盖的血清型导致的疾病又分别占65.3%、42.1%和61.4%。携带率在儿童中最高,接种疫苗儿童中PCV7血清型的低携带率和疾病患病率体现了疫苗的直接影响,而未接种疫苗的父母和老年人中的类似观察结果则暗示了群体保护的间接影响。